Research programme: malaria vaccine - Etna
Latest Information Update: 20 Mar 2014
At a glance
- Originator Etna Biotech
- Class Vaccines
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Malaria
Most Recent Events
- 20 Mar 2014 Preclinical development is ongoing in Italy
- 27 Dec 2006 Preclinical trials in Malaria in Italy (Injection)